Login to Your Account

First Pivotal Phase III Positive

Investors Watch, Wait on More Data with Mipomersen In LDL

By Randy Osborne

Thursday, May 21, 2009
Isis Pharmaceuticals Inc. and Genzyme Corp.'s statin add-on mipomersen met its Phase III endpoint in the rare disorder homozygous familial hypercholesterolemia (hoFH), but six trial dropouts from 34 patients bothered Wall Street. One was caused by hiked liver enzymes, which has been a problem in other studies, too. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription